Biosimilar Notice Ruling 'Nonsensical,' High Court Hears
The Federal Circuit reached a "nonsensical" conclusion that biosimilar makers must wait for product approval before giving notice of sales to rivals, a top trade group told the U.S. Supreme Court...To view the full article, register now.
Already a subscriber? Click here to view full article